124 related articles for article (PubMed ID: 25704438)
1. Gene mutation order affects cancer behaviour.
Bagcchi S
Lancet Oncol; 2015 Mar; 16(3):e112. PubMed ID: 25704438
[No Abstract] [Full Text] [Related]
2. [Molecular biology and new drug therapy for myeloproliferative neoplasm].
Kitanaka A; Shide K; Shimoda K
Rinsho Ketsueki; 2013 Oct; 54(10):1697-703. PubMed ID: 24064819
[No Abstract] [Full Text] [Related]
3. Clonogenic versus morphogenic mutations in myeloid neoplasms: chronologic observations in a U2AF1, TET2, CSF3R and JAK2 'co-mutated' myeloproliferative neoplasm suggest a hierarchical order of mutations and potential predictive value for kinase inhibitor treatment response.
Gerlach MM; Lundberg P; Halter J; Arranto C; Wenzel F; Dirnhofer S; Tzankov A
Leuk Lymphoma; 2018 Aug; 59(8):1994-1997. PubMed ID: 29199511
[No Abstract] [Full Text] [Related]
4. A prospective evaluation of vitamin B1 (thiamine) level in myeloproliferative neoplasms: clinical correlations and impact of JAK2 inhibitor therapy.
Gangat N; Phelps A; Lasho TL; Finke CM; Vallapureddy R; Hanson CA; Ketterling RP; Patnaik MM; Pardanani A; Tefferi A
Blood Cancer J; 2019 Jan; 9(2):11. PubMed ID: 30679417
[No Abstract] [Full Text] [Related]
5. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
6. Dynamics of JAK2 V617F allele burden of CD34+ haematopoietic progenitor cells in patients treated with ruxolitinib.
Angona A; Alvarez-Larrán A; Bellosillo B; Longarón R; Fernández-Rodríguez C; Besses C
Br J Haematol; 2016 Feb; 172(4):639-42. PubMed ID: 26115187
[No Abstract] [Full Text] [Related]
7. Myeloproliferative neoplasms 5 years after discovery of JAK2V617F: what is the impact of JAK2 inhibitor therapy?
Tibes R; Mesa RA
Leuk Lymphoma; 2011 Jul; 52(7):1178-87. PubMed ID: 21599574
[TBL] [Abstract][Full Text] [Related]
8. A common genetic mechanism in malignant bone marrow diseases.
Levine RL; Carroll M
N Engl J Med; 2009 May; 360(22):2355-7. PubMed ID: 19474434
[No Abstract] [Full Text] [Related]
9. Effect of mutation order on myeloproliferative neoplasms.
Delhommeau F
N Engl J Med; 2015 May; 372(19):1865. PubMed ID: 25946290
[No Abstract] [Full Text] [Related]
10. Effect of mutation order on myeloproliferative neoplasms.
Kent DG; Ortmann CA; Green AR
N Engl J Med; 2015 May; 372(19):1865-6. PubMed ID: 25946289
[No Abstract] [Full Text] [Related]
11. Genetics: Myeloproliferative neoplasms—order of mutations counts!
Hutchinson L
Nat Rev Clin Oncol; 2015 Apr; 12(4):187. PubMed ID: 25734632
[No Abstract] [Full Text] [Related]
12. Myeloproliferative Neoplasms: A Contemporary Review.
Tefferi A; Pardanani A
JAMA Oncol; 2015 Apr; 1(1):97-105. PubMed ID: 26182311
[TBL] [Abstract][Full Text] [Related]
13. Cancer evolution constrained by mutation order.
Swanton C
N Engl J Med; 2015 Feb; 372(7):661-3. PubMed ID: 25671259
[No Abstract] [Full Text] [Related]
14. Tumorigenesis: Order matters.
Seton-Rogers S
Nat Rev Genet; 2015 Apr; 16(4):193. PubMed ID: 25783446
[No Abstract] [Full Text] [Related]
15. Tumorigenesis: Order matters.
Seton-Rogers S
Nat Rev Cancer; 2015 Apr; 15(4):196-7. PubMed ID: 25740421
[No Abstract] [Full Text] [Related]
16. Mechanisms of Resistance to JAK2 Inhibitors in Myeloproliferative Neoplasms.
Meyer SC
Hematol Oncol Clin North Am; 2017 Aug; 31(4):627-642. PubMed ID: 28673392
[TBL] [Abstract][Full Text] [Related]
17. JAK-mutant myeloproliferative neoplasms.
Levine RL
Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
[TBL] [Abstract][Full Text] [Related]
18. Janus kinase 2 mutations in Philadelphia negative chronic myeloproliferative disorders: clinical implications.
Panani AD
Cancer Lett; 2009 Oct; 284(1):7-14. PubMed ID: 19269737
[TBL] [Abstract][Full Text] [Related]
19. JAK inhibition: the key to treating myeloproliferative neoplasm?
Tibes R; Bogenberger JM; Mesa RA
Expert Rev Hematol; 2012 Dec; 5(6):583-5. PubMed ID: 23216589
[No Abstract] [Full Text] [Related]
20. Myeloproliferative neoplasms: from origins to outcomes.
Nangalia J; Green AR
Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):470-479. PubMed ID: 29222295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
